We detected EGFR and HER2 amplification in 7 and 11% of ESCC specimens and our results support a rationale for introducing anti-EGFR and anti-HER2 antibody therapies to the treatment of patients with ESCC. Here, EGFR is linked to esophageal squamous cell carcinoma.